You are here: Home » Reuters » News
Business Standard

Pfizer, Astellas prostate cancer drug succeeds key trial


By Divya Grover(Reuters) - Pfizer Inc and Japan's Astellas Pharma Inc said on Thursday their prostate cancer drug met the main goal of a trial testing it for a more common form of the disease.The drug, Xtandi, is already approved to treat metastatic castration-resistant prostate cancer (CRPC) - where the cancer has spread to other parts of the body - and raked in U.S. sales of $141 million in the second quarter for Pfizer.An approval to treat non-metastatic CRPC would significantly boost sales of Xtandi, which Pfizer got access to when it bought Medivation for $14 billion last year. Astellas ...

This article is no longer available in our repository.

There could be multiple reasons for this.

First Published: Thu, September 14 2017. 20:24 IST